Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"$2,115.0 million","upfrontCash":"$260.0 million","newsHeadline":"Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA\u00ae (Lutetium Lu 177 Dotatate)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Perspective Therapeutics","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"$28.0 million","newsHeadline":"Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Lantheus Holding

    Menu

    Lantheus Holding

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Lantheus Holding

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)

              Details:

              Lutathera-Generic (Lutetium Lu 177 Dotatate) is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

              Lead Product(s): Dotatate Lutenium Lu-177

              Therapeutic Area: Oncology Product Name: Lutathera-Generic

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 11, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lantheus Holding

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics

              Details:

              Under the agreement, Lantheus obtains an exclusive license for Perspective’s Pb212-VMT-⍺-NET, a clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors.

              Lead Product(s): 212Pb-VMT-alpha-NET

              Therapeutic Area: Oncology Product Name: 212Pb-VMT-alpha-NET

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Perspective Therapeutics

              Deal Size: $61.0 million Upfront Cash: $28.0 million

              Deal Type: Agreement January 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lantheus Holding

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

              Details:

              PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy under phase 3 clinical development for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

              Lead Product(s): [Lu-177]-PNT2002

              Therapeutic Area: Oncology Product Name: [Lu-177]-PSMA-I&T

              Highest Development Status: Phase III Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Point Biopharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lantheus Holding

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

              Details:

              PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

              Lead Product(s): 177Lu-PNT2002

              Therapeutic Area: Oncology Product Name: PNT2002

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: Point Biopharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lantheus Holding

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

              Details:

              Lu-177-PSMA-I&T (Lu-177-PNT2002) is a PSMA-Targeted therapy for mCRPC. PSMA is overexpressed in the vast majority of prostate cancers, but very limited to normal tissues. PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

              Lead Product(s): 177Lu-PNT2002

              Therapeutic Area: Oncology Product Name: 177Lu-PSMA-I&T

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: Point Biopharma

              Deal Size: $2,115.0 million Upfront Cash: $260.0 million

              Deal Type: Collaboration November 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lantheus Holding

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development

              Details:

              As part of the agreement with Novartis, Lantheus will provide PYLARIFY for the selection of patients with prostate cancer and Novartis will provide all PYLARIFY related clinical imaging data to Lantheus.

              Lead Product(s): Lutetium-177 Vipivotide Tetraxetan

              Therapeutic Area: Oncology Product Name: Pluvicto

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY